Aspects of hyperglycemia contribution to arterial stiffness and cardiovascular complications in patients with type 1 diabetes

Journal of Diabetes Science and Technology

Volumn 10, Issue 5, 2016, Pages 1059-1064

  Gordin, Daniel ^a,b   Groop, Per Henrik ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Arterial stiffness; Augmentation index; Cardiac repolarization; Diabetes; Endothelial dysfunction; Pulse wave velocity

Indexed keywords

BIOLOGICAL MARKER; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; PIOGLITAZONE; SUPEROXIDE;

ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTICLE; AUGMENTATION INDEX; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; HEART REPOLARIZATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NOCTURNAL HYPOGLYCEMIA; PULSE WAVE; RESPIRATORY CHAIN; RETINOPATHY; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC ANGIOPATHIES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; VASCULAR STIFFNESS;

EID: 85012981869     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296816636894     Document Type: Article

References (46)

1. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in T1D: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28: 2019-2024.
2. Klein R, Klein BE, Moss SE Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124:90-96.
3. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25:971-1010.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
5. Duprez DA. Arterial stiffness and endothelial function: key players in vascular health. Hypertension. 2010;55:612-613.
6. Nichols WW, O'Rourke MF. McDonald's Blood Flow in Arteries. Theoretic, Experimental and Clinical Principles. 4th ed. London, UK: Edward Arnold; 1998.
7. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Hypertension. 1993;22:876-883.
8. Mullan BA, Ennis CN, Fee H, Young IS, McCance DR. Protective effects of ascorbic acid on arterial hemodynamics during acute hyperglycemia. Am J Physiol Heart Circ Physiol. 2004;287:1262-1268.
9. Gordin D, Rönnback M, Forsblom C, Heikkilä O, Saraheimo M, Groop PH. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with T1D. Diabetologia. 2007;50:1808-1814.
10. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated T1D mellitus. Cardiovasc Diabetol. 2014;13:28.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
12. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24:969-974.
13. Gordin D, Forsblom C, Rönnback M, et al. Acute hyperglycaemia induces an inflammatory response in young patients with T1D. Ann Med. 2008;40:627-633.
14. Ceriello A, Novials A, Ortega E, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in T1D. Diabetes Care. 2013;36:2346-2350.
15. Tatersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991;8:49-58.
16. Robinson RT, Harris ND, Ireland RH, Macdonald IA, Heller SR. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with T1D. Diabetologia. 2004;47:312-315.
17. Gordin D, Forsblom C, Rönnback M, Groop PH. Acute hyperglycaemia disturbs cardiac repolarization in T1D. Diabet Med. 2008;25:101-105.
18. Brooks B, Molyneaux L, Yue DK. Augmentation of central arterial pressure in T1D. Diabetes Care. 1999;22:1722-1727.
19. Kool MJ, Lambert J, Stehouwer CD, Hoeks AP, Struijker Boudier HA, Van Bortel LM. Vessel wall properties of large arteries in uncomplicated IDDM. Diabetes Care. 1995;18:618-624.
20. Urbina EM, Wadwa RP, Davis C, et al. Prevalence of increased arterial stiffness in children with T1D mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. J Pediatr. 2010;156:731-737.
21. Heilman K, Zilmer M, Zilmer K, et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with T1D. Diabetes Res Clin Pract. 2009;84:168-173.
22. Giannattasio C, Failla M, Grappiolo A, Gamba PL, Paleari F, Mancia G. Progression of large artery structural and functional alterations in T1D. Diabetologia. 2001;44:203-208.
23. Gordin D, Wadén J, Forsblom C, et al. Arterial stiffness and vascular complications in patients with T1D: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann Med. 2012;44:196-204.
24. Rönnback M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A, Groop PH. Altered age-related blood pressure pattern in T1D. Circulation. 2004;110:1076-1082.
25. Gordin D, Wadén J, Forsblom C, et al. Pulse pressure predicts incident cardiovascular disease but not diabetic nephropathy in patients with T1D (The FinnDiane Study). Diabetes Care. 2011;34:886-891.
26. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in T1D. Diabetes. 2009;58:1651-1658.
27. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23:489-494.
28. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:1924-1928.
29. Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with T1D. Diabetes Care. 2013;36:1827-1833.
30. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM. 2002;95:3-13.
31. Takemoto M, Yokote K, Nishimura M, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:624-628.
32. Gordin D, Forsblom C, Panduru NM, et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with T1D. Diabetes Care. 2014;37:2593-2600.
33. Fok H, Cruickshank JK. Future treatment of hypertension: shifting the focus from blood pressure lowering to arterial stiffness modulation? Curr Hypertens Rep. 2015;17:67.
34. Laurent S, Kingwell B, Bank A, Weber M, Struijker-Boudier H. Clinical applications of arterial stiffness: therapeutics and pharmacology. Am J Hypertens. 2002;15:453-458.
35. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
36. Kass D, Shapiro E, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-1470.
37. Fujimoto N, Hastings JL, Carrick-Ranson G, et al. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. Circ Heart Fail. 2013;6:1155-1164.
38. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-2499.
39. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta: a novel physiological action of insulin on large blood vessels. Hypertension. 1999;33:1118-1122.
40. Westerbacka J, Uosukainen A, Mäkimattila S, Schlenzka A, Yki-Järvinen H. Insulin-induced decrease in large artery stiffness is impaired in uncomplicated T1D mellitus. Hypertension. 2000;35:1043-1048.
41. Wilhelm B, Weber MM, Kreisselmeier HP, et al. Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycaemic clamp. J Diabetes Sci Technol. 2007;1:582-589.
42. Greenfield JR, Samaras K, Chisholm DJ, Campbell LV. Effect of postprandial insulinemia and insulin resistance on measurement of arterial stiffness (augmentation index). Int J Cardiol. 2007;114:50-56.
43. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110: 26-37.
44. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428.
45. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180-1193.
46. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.